Eribulin: A Ray of Hope for Hormone-Refractory Metastatic Breast Cancer?
For women battling hormone-refractory metastatic breast cancer (MBC), treatment options can feel limited. This article explores how eribulin mesylate, a non-taxane microtubule dynamics inhibitor, provides a potential lifeline, offering improved outcomes and quality of life.